Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

InvestingPro data shows the stock has demonstrated strong resilience, often moving independently of broader market trends. The focus is on the potential of enobosarm, Veru's investigational drug, to ...

Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...